PDGFRA and gastrointestinal stromal tumor: The oncogenic tyrosine kinase activity of KIT and PDGFRA was significantly inhibited by imatinib, resulting in obviously improved prognosis of GIST patients harboring oncogenic mutations in KIT/PDGFRA.